The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Arkadiusz Z. Dudek

University of Minnesota

MMC 480

420 Delaware St. SE

Minneapolis

U.S.A

[email]@umn.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of Minnesota, MMC 480, 420 Delaware St. SE, Minneapolis, U.S.A. 2011 - 2012
  • Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, U.S.A. 2003 - 2011
  • University of Minnesota Comprehensive Cancer Center, Minneapolis, Minnesota 55455, USA. 2006 - 2008

References

  1. Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy. Wang, H., Cao, Q., Dudek, A.Z. Anticancer Res. (2012) [Pubmed]
  2. Polymorphisms in DNA Repair Gene XRCC1 and Skin Cancer Risk: A Meta-analysis. Zhang, H., Li, W., Franklin, M.J., Dudek, A.Z. Anticancer Res. (2011) [Pubmed]
  3. MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. Jasinski, P., Zwolak, P., Terai, K., Vogel, R.I., Borja-Cacho, D., Dudek, A.Z. Anticancer Res. (2011) [Pubmed]
  4. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Spector, E., Franklin, M.J., Truskinovsky, A.M., Dudek, A.Z. Acta. Oncol (2010) [Pubmed]
  5. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Dudek, A.Z., Yee, R.T., Manivel, J.C., Isaksson, R., Yee, H.O. Anticancer Res. (2010) [Pubmed]
  6. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. Dudek, A.Z., Lesniewski-Kmak, K., Larson, T., Dragnev, K., Isaksson, R., Gupta, V., Maddaus, M.A., Kratzke, R.A. J. Thorac. Oncol (2009) [Pubmed]
  7. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Dudek, A.Z., Lesniewski-Kmak, K., Shehadeh, N.J., Pandey, O.N., Franklin, M., Kratzke, R.A., Greeno, E.W., Kumar, P. Br. J. Cancer (2009) [Pubmed]
  8. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Dudek, A.Z., Zolnierek, J., Dham, A., Lindgren, B.R., Szczylik, C. Cancer (2009) [Pubmed]
  9. Safety of nab-paclitaxel plus sunitinib: analysis of three cases. Dudek, A.Z., Nguyen, S. Anticancer Res. (2008) [Pubmed]
  10. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek, A.Z., Mescher, M.F., Okazaki, I., Math, V.T., Luo, X., Curtsinger, J.M., Miller, J.S. Am. J. Clin. Oncol. (2008) [Pubmed]
  11. Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia. Dudek, A.Z., Chereddy, S., Nguyen, S., Wagner, J.E., Maddaus, M. J. Thorac. Oncol (2008) [Pubmed]
  12. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. Dudek, A.Z., Larson, T., McCleod, M.J., Schneider, D.J., Dowell, J.E., Banerjee, T.K., Pandya, K.J., Bromund, J.L., Chen, R., Monberg, M.J., Obasaju, C.K. J. Thorac. Oncol (2008) [Pubmed]
  13. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Dudek, A.Z., Zwolak, P., Jasinski, P., Terai, K., Gallus, N.J., Ericson, M.E., Farassati, F. Invest. New. Drugs (2008) [Pubmed]
  14. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. Dudek, A.Z., Larson, T., Keshtgarpour, M., Kumar, P. Am. J. Clin. Oncol. (2007) [Pubmed]
  15. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Dudek, A.Z., Bodempudi, V., Welsh, B.W., Jasinski, P., Griffin, R.J., Milbauer, L., Hebbel, R.P. Br. J. Cancer (2007) [Pubmed]
  16. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Dudek, A.Z., Kmak, K.L., Koopmeiners, J., Keshtgarpour, M. Lung. Cancer (2006) [Pubmed]
  17. Hematopoietic stem cell transplant-related airflow obstruction. Dudek, A.Z., Mahaseth, H. Curr. Opin. Oncol (2006) [Pubmed]
  18. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Dudek, A.Z., Arodz, T., Gálvez, J. Comb. Chem. High Throughput Screen. (2006) [Pubmed]
  19. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Dudek, A.Z., Leśniewski-Kmak, K., Bliss, R.L., Brunstein, C., Condon, D.L., Kratzke, R.A. Lung (2005) [Pubmed]
  20. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Dudek, A.Z., Mahaseth, H. Cancer Invest. (2005) [Pubmed]
  21. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Dudek, A.Z., Nesmelova, I., Mayo, K., Verfaillie, C.M., Pitchford, S., Slungaard, A. Blood (2003) [Pubmed]
  22. Molecular targets in the inhibition of angiogenesis. Dudek, A.Z., Pawlak, W.Z., Kirstein, M.N. Expert Opin. Ther. Targets (2003) [Pubmed]
  23. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Dudek, A.Z., Mahaseth, H., DeFor, T.E., Weisdorf, D.J. Biol. Blood Marrow Transplant. (2003) [Pubmed]
 
WikiGenes - Universities